MBRX 8-K
Moleculin Biotech, Inc. (MBRX)
8-K
2026-04-15
For: 2026-04-15
View Original
Added on
April 15, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 15, 2026
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File No.)
|
(I.R.S. Employer Identification No.)
|
(Address of principal executive offices and zip code)
(713 ) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol (s)
|
Name of each exchange on which registered
|
|
|
|
The
|
Item 5.07 Submission of Matters to a Vote of Security Holders.
On April 15, 2026, the Company held a Special Meeting of Stockholders (the "Special Meeting"). As of February 20, 2026, the record date for the Special Meeting, there were 4,933,110 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Special Meeting, of which 2,382,989 shares were present in person or represented by proxy, which constituted a quorum. The holders of shares of our common stock are entitled to one vote for each share held. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Special Meeting. Each of these proposals is described in greater detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on March 9, 2026 (the “Proxy Statement”).
Proposal 1. Approve the Nasdaq Proposal for Certain Warrants Issued on February 20, 2026 - The Company's stockholders approved the issuance of up to 6,367,956 shares of Company common stock upon the exercise of certain warrants issued on February 20, 2026, by the following vote:
|
Votes For
|
Votes Against
|
Abstain
|
Broker Non-Votes
|
|||
|
854,036
|
211,394
|
7,489
|
1,310,070
|
Proposal 2. Approve an Amendment to Change the Company’s Name from Moleculin Biotech, Inc. to Moleculin Inc. - The Company's stockholders did not approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to change the Company’s name from Moleculin Biotech, Inc. to Moleculin Inc. (as such vote required a majority of the outstanding shares on the record date to vote “For” which did not occur) by the following vote:
|
Votes For
|
Votes Against
|
Abstain
|
Broker Non-Votes
|
|||
|
2,015,174
|
82,841
|
284,974
|
N/A
|
Proposal 3. Approve an Adjournment - The Company's stockholders approved an adjournment, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Proposal or the Name Change Proposal, by the following vote:
|
Votes For
|
Votes Against
|
Abstain
|
Broker Non-Votes
|
|||
|
616,186
|
169,854
|
286,879
|
1,310,070
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MOLECULIN BIOTECH, INC.
|
|
|
Date: April 15, 2026
By: /s/ Jonathan P. Foster
Jonathan P. Foster
Chief Financial Officer
|